NASDAQ: MTEMMolecular Templates Inc Stock
$0.46+0.01 (+2.22%)
Updated May 26, 2023
MTEM Price
$0.46
Fair Value Price
$1.02
Market Cap
$25.92M
52 Week Low
$0.31
52 Week High
$1.23
P/E
-0.43x
P/B
-13.57x
P/S
0.45x
PEG
N/A
Dividend Yield
N/A
Revenue
$47.90M
Earnings
-$60.26M
Gross Margin
100%
Operating Margin
-115%
Profit Margin
-125.8%
Debt to Equity
-42.1
Operating Cash Flow
-$81M
Beta
1.26
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MTEM Overview
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MTEM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MTEM ($0.46) is undervalued by 54.96% relative to our estimate of its Fair Value price of $1.02 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
MTEM ($0.46) is significantly undervalued by 54.96% relative to our estimate of its Fair Value price of $1.02 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
MTEM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MTEM due diligence checks available for Premium users.
Be the first to know about important MTEM news, forecast changes, insider trades & much more!
MTEM News
Valuation
MTEM fair value
Fair Value of MTEM stock based on Discounted Cash Flow (DCF)
Price
$0.46
Fair Value
$1.02
Undervalued by
54.96%
MTEM ($0.46) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MTEM ($0.46) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MTEM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MTEM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.43x
Industry
11.86x
Market
54.23x
MTEM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-13.57x
Industry
5.18x
MTEM's financial health
Profit margin
Revenue
$36.6M
Net Income
$10.8M
Profit Margin
29.6%
MTEM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MTEM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$78.5M
Liabilities
$80.4M
Debt to equity
-42.1
MTEM's short-term assets ($51.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MTEM's short-term assets ($51.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MTEM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MTEM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.4M
Investing
$26.0M
Financing
$0.0
MTEM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MTEM vs Biotech Stocks
Molecular Templates Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.